Replies to post #246067 on NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

you wrote:

One interview where the top 100 lived beyond 5 years whereas with SOC they would on average all be dead at 15 months.

1) with SOC I believe the mOS is (was) around 15 months ... in which case they would not all be dead at 15 months, but half would be dead, and the other half would be alive. On average.

2) If Les G is indicating in the interview that the total trial population of 331 patients (treatment + placebo) is experiencing mOS of 2 years, then 24 months would indeed provide some improvement versus 15 months. Significant if you consider the percentage improvement. But it is not like the entire population is living many years longer.
It seems to me that the blinded results, as well as prior indications from Linda Liau etc, are hinting that the trial version of DCVax-L is only proving to be very beneficial to maybe 20% or 30% of those patients treated. So this begs the question ... if it is unknown in advance which patients are most likely to benefit, would DCVax-L have good chance of being approved, despite not being (very) effective for perhaps 70% to 80% of patients? And taking into account that the drug treatment might cost well over $100,000 per patient?

3) regarding the top 100 patients .... is the (KM derived) mOS in excess of 5 years? Or have the top 100 all survived longer than 5 years. Big difference.